Wilson Sonsini advised Chroma Medicine on the deal. Genomic medicine company Chroma Medicine announced that it had completed a $135 million Series B financing, which was...
You must be a Standard 1 Year member to access this content.
Orrick advised Third Rock Ventures on the deal while Wilson Sonsini represented CARGO Therapeutics. Third Rock Ventures announced its investment in the $200 million Series A financing...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ascidian Therapeutics on the deal. Life sciences venture capital firm ATP announced the launch of new biotechnology company Ascidian Therapeutics....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini and Honigman advised Prime Medicine on the deal, while Davis Polk advised the joint book-running managers. Prime Medicine, Inc., a biotechnology company committed to...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Marengo on the deal. Ipsen and Marengo Therapeutics announced a strategic partnership to advance two of Marengo’s preclinical STAR platform-generated...
You must be a Standard 1 Year member to access this content.
Davis Polk & Wardwell, Mayer Brown, and Mishcon de Reya advised Gilead, while Goodwin Procter and Wilson Sonsini Goodrich & Rosati advised MiroBio on the deal....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati and Goodwin advised MiroBio on the deal. MiroBio, a leader in the development of checkpoint agonists to treat autoimmune diseases, announced...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised CellPoint on the deal. Walder Wyss has advised +ND Capital, while Baker McKenzie advised CellPoint and AboundBio. Galapagos, a fully...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised SR One on the deal. Simcha Therapeutics, a biotechnology company developing cytokine-based cancer immunotherapies, announced the closing of a $40...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Acadia Pharmaceutical on the deal while Wilson Sonsini represented Stoke Therapeutics. Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced its collaboration agreement with Stoke Therapeutics, Inc....
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Chroma Medicine on the deal. Chroma Medicine, a new genomic medicine company pioneering epigenetic editing, launched with $125 million in...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Totient on the deal. AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced the acquisition...
You must be a Standard 1 Year member to access this content.
